G1 Therapeutics, Inc (GTHX)

Etorro trading 970x250
G1 Therapeutics, Inc (GTHX) Logo

About G1 Therapeutics, Inc

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina. Address: 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709

G1 Therapeutics, Inc News and around…

Latest news about G1 Therapeutics, Inc (GTHX) common stock and company :

G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
29 Nov, 2021 Yahoo! Finance

Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug conjugate (ADC), Trodelvy® (sacituzumab govitecan-hz

First Week of GTHX July 2022 Options Trading
19 Nov, 2021 FinancialContent

Investors in G1 Therapeutics Inc (GTHX) saw new options become available this week, for the July 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
12 Nov, 2021 Yahoo! Finance

- Exploratory Analysis Investigated Immune Mechanisms Underlying The Significant Improvement In Overall Survival Shown In The Phase 2 TNBC Trial, Results Of Which Were Presented At 2020 San Antonio Breast Cancer Symposium - - Responders Showed Increased T Cell Function as Measured by Greater Cytokine Production - - Responders Had Fewer Immune-Suppressing Cells Known as Myeloid-Derived Suppressor Cells - RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq

Analysts Anticipate PRFZ To Hit $221
12 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $220.92 per unit.

G1 Therapeutics to Participate in Two Upcoming Conferences
10 Nov, 2021 Yahoo! Finance

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences. On November 17, 2021 at 8:00 AM EST, G1’s Chief Executive Officer Jack Bailey will present at the Stifel 2021 Virtual Healthcare Conference. On December 1, 2021 at 12:35 PM EST, Mr. Bailey will participate in a fireside chat at the 4th Annual Evercore ISI HealthCON

G1 Therapeutics (NASDAQ:GTHX) shareholders have endured a 66% loss from investing in the stock three years ago
06 Nov, 2021 Yahoo! Finance

G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders should be happy to see the share price up 28% in the last month. But...

Analyst Ratings For G1 Therapeutics
04 Nov, 2021 FinancialContent

Analysts have provided the following ratings for G1 Therapeutics (NASDAQ:GTHX) within the last quarter: Bullish Somewhat ...

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021
04 Nov, 2021 FinancialContent

Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ:MRCC) was changed from Neutral to Buy. For ...

G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript
03 Nov, 2021 FinancialContent

GTHX earnings call for the period ending September 30, 2021.

Recap: G1 Therapeutics Q3 Earnings
03 Nov, 2021 FinancialContent

G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what ...

G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
03 Nov, 2021 Yahoo! Finance

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 2.91% and 12.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
03 Nov, 2021 Yahoo! Finance

- Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication of Permanent J-Code for COSELA - - Initiation of Two New Phase 2 Trials Expected in the Fourth Quarter of 2021 to Further Investigate Trilaciclib’s Immune-Based Mechanism of Action (MOA) and Potential Benefits in Combination with an Antibody-Drug Conjugate (ADC) - - Amended Debt Facility Exten

Earnings Preview: G1 Therapeutics (GTHX) Q3 Earnings Expected to Decline
27 Oct, 2021 Yahoo! Finance

G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021
20 Oct, 2021 Yahoo! Finance

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2021 on Wednesday, November 3, 2021 at 8:30 a.m. ET. The live call may be accessed by dialing (866) 763-6020 (domestic) or (210) 874-7713 (international) and entering the conference code: 4404009. The live and archived webcast will be available on the

22 Stocks Moving in Friday's Pre-Market Session
15 Oct, 2021 FinancialContent

Gainers LM Funding America, Inc. (NASDAQ: LMFA) rose 39.5% to $4.80 in pre-market trading after declining around 15% on Thursday. ...

Add Up The Parts: VBR Could Be Worth $200
12 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Value ETF (VBR), we found that the implied analyst target price for the ETF based upon its underlying holdings is $200.13 per unit.

Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy
07 Oct, 2021 Yahoo! Finance

Proactive use of trilaciclib prior to chemotherapy in certain patients significantly reduced the use of G-CSFs, ESAs, and RBC transfusions on or after week five of chemotherapyRESEARCH TRIANGLE PARK, N.C., Oct. 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell lung cancer (ES

G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
01 Oct, 2021 Yahoo! Finance

Effective Today, New J-code to Streamline ReimbursementRESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for COSELA™ (trilaciclib) that was issued in July 2021 by the Centers for Medicare & Medicaid Services (CMS) is now effective for provider billing for all sites of care. The permanent J-code for COSELA, J1448 (Injection, trilaciclib, 1mg.), published onl

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep, 2021 FinancialContent

Upgrades For Cabot Oil & Gas Corp (NYSE:COG), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. For the ...

10 Biggest Price Target Changes For Thursday
30 Sep, 2021 FinancialContent

Jefferies raised Perrigo Company plc (NYSE: PRGO) price target from $45 to $63. Perrigo shares jumped 13.3% to $49.27 in pre-market ...

What Type Of Shareholders Own The Most Number of G1 Therapeutics, Inc. (NASDAQ:GTHX) Shares?
22 Sep, 2021 Yahoo! Finance

The big shareholder groups in G1 Therapeutics, Inc. ( NASDAQ:GTHX ) have power over the company. Large companies...

G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
15 Sep, 2021 FinancialContent

- New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities -

Analysts Expect VTWG Will Reach $269
09 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $268.83 per unit.

G1 Therapeutics to Participate in Two Upcoming September Conferences
03 Sep, 2021 FinancialContent
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Sep, 2021 FinancialContent
First Week of GTHX April 2022 Options Trading
20 Aug, 2021 FinancialContent

Investors in G1 Therapeutics Inc (GTHX) saw new options begin trading this week, for the April 2022 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 237 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Return on Capital Employed Overview: G1 Therapeutics
20 Aug, 2021 FinancialContent

Pulled from Benzinga Pro data G1 Therapeutics (NASDAQ:GTHX) reported Q2 sales of $6.60 million. Earnings fell to a loss of $38.19 ...

IEIH's Underlying Holdings Imply 13% Gain Potential
09 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Industry Analysts Just Made A Meaningful Upgrade To Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Revenue Forecasts
08 Aug, 2021 Yahoo! Finance

G1 Therapeutics, Inc. ( NASDAQ:GTHX ) shareholders will have a reason to smile today, with the analysts making...

Here's Why G1 THERAPEUTICS (GTHX) is Poised for a Turnaround After Losing 16.4% in 4 Weeks
05 Aug, 2021 Yahoo! Finance

The heavy selling pressure might have exhausted for G1 THERAPEUTICS (GTHX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

G1 Therapeutics, Inc (GTHX) is a NASDAQ Common Stock listed in , ,

970x250